Thanks again, good to get some insight.
What do you guys think of DCF valuations with reversions for bio companies.
ie. would a 5 year term of cashflows at a discount rate of 8%, together with a reversion at 7% be applicable.
agm today, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)